-
Study Results of Orelabrutinib in Patients with ITP Published by the American Journal of Hematology
PharmaSources
April 18, 2024
The study provides compelling evidence for the potential of orelabrutinib as a safe and effective therapy for patients with ITP.
-
Toxys Reports Positive Results from the OECD Ring Trial Validation of ToxTracker in a Peer-Reviewed Article
Biotech Newswire
April 10, 2024
Toxys announces the peer-reviewed publication of the positive results from an international interlaboratory validation of ToxTracker©.
-
Celonic Launches New GS-CHOvolution® Cell Line Expression System
Biotech Newswire
April 10, 2024
GS-CHOvolution® is based on Revvity’s CHOSOURCE™ expression platform and TnT transposon technology.
-
Osteolabs to Present New Clinical Data from Over 2.400 OsteoTest Routine Samples at the WCO-IOF-ESCEO Congress
Biotech Newswire
April 10, 2024
New data fully supporting potential for OsteoTest to qualify as new universal diagnostic method for early osteoporosis risk assessment and therapeutic control.
-
Sartorius and TheWell Bioscience Partner to Enable More Accurate Predictions in Drug Discovery
Biotech Newswire
April 10, 2024
TheWell Bioscience is a pioneer in the field of animal-free hydrogels and bioinks, critical components for the creation of 3D biomimicking platforms.
-
First Study Using Biomimetic AI Digital Twins And Multiomics in Genetics Research
Biotech Newswire
April 07, 2024
The Application of Knowledge Engineering via the use of a Biomimetic Digital Twin Ecosystem, Phenotype DrivenVariant Analysis, and Exome Sequencing to Understand the Molecular Mechanisms of Disease.
-
University of Liverpool to Use Touchlight’s Rapid Enzymatic dbDNA in Fully Personalised Neoantigen Cancer Vaccine Clinical Study
Biotech Newswire
April 07, 2024
Touchlight announced an agreement with University of Liverpool for the use of dbDNA in the development of a fully-personalised therapeuticneoantigen DNA vaccine for patients with non-small cell lung cancer.
-
ProBioGen and DIOSynVax Partner to Manufacture Groundbreaking Multivalent Vaccine for Hemorrhagic Fever
Biotech Newswire
April 01, 2024
ProBioGen’s MVA CR19vector will be used to deliver the three HF vaccine antigens.
-
InnoCare Announces Dosing of First Patient in Clinical Study of the Combination of SHP2 Inhibitor ICP-189 and EGFR Inhibitor Furmonertinib
PharmaSources
April 01, 2024
ICP-189 is a potent and selective oral allosteric inhibitor of SHP2, developed by InnoCare for the treatment of solid tumors as a single agent and/or in combination with other antitumor agents.
-
InnoCare Releases 2023 Results and Business Highlights
PharmaSources
March 29, 2024
InnoCare Pharma, a leading biopharmaceutical company focusing on cancer and autoimmune diseases, today announced the 2023 annual results as of 31 December 2023.